Lidén Åsa, Karlsen Tine Veronika, Guss Bengt, Reed Rolf K, Rubin Kristofer
Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway.
Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Box 7036, SE-750 07, Uppsala, Sweden.
Exp Physiol. 2018 May 1;103(5):629-634. doi: 10.1113/EP086902.
What is the central question of this study? Collagen-binding β -integrins function physiologically in cellular control of dermal interstitial fluid pressure (P ) in vivo and thereby participate in control of extravascular fluid volume. During anaphylaxis, simulated by injection of compound 48/80, integrin α β takes over this physiological function. Here we addressed the question whether integrin α β can replace collagen-binding β -integrin to maintain a long-term homeostatic P . What is the main finding and its importance? Mice lacking the collagen-binding integrin α β show a complex dermal phenotype with regard to the interstitial physiology apparent in the control of P . Notably dermal P is not lowered with compound 48/80 in these animals. Our present data imply that integrin α β is the likely candidate that has taken over the role of collagen-binding β -integrins for maintaining a steady-state homeostatic P . A better understanding of molecular processes involved in control of P is instrumental for establishing novel treatment regimens for control of oedema formation in anaphylaxis and septic shock.
Accumulated data indicate that cell-mediated contraction of reconstituted collagenous gels in vitro can serve as a model for cell-mediated control of interstitial fluid pressure (P ) in vivo. A central role for collagen-binding β -integrins in both processes has been established. Furthermore, integrin α β takes over the role of collagen-binding β -integrins in mediating contraction after perturbations of collagen-binding β -integrins in vitro. Integrin α β is also instrumental for normalization of dermal P that has been lowered due to mast cell degranulation with compound 48/80 (C48/80) in vivo. Here we demonstrate a role of integrin α β in maintaining a long term homeostatic dermal P in mice lacking the collagen-binding integrin α β (α11 mice). Measurements of P were performed after circulatory arrest. Furthermore, cell-mediated integrin α β -directed contraction of collagenous gels in vitro depends on free access to a collagen site known to bind several extracellular matrix (ECM) proteins that form substrates for α β -directed cell attachment, such as fibronectin and fibrin. A streptococcal collagen-binding protein, CNE, specifically binds to and blocks this site on the collagen triple helix. Here we show that whereas CNE perturbed α β -directed and platelet-derived growth factor BB-induced normalization of dermal P after C48/80, it did not affect α β -dependent maintenance of a homeostatic dermal P . These data imply that dynamic modification of the ECM structure is needed during acute patho-physiological modulations of P but not for long-term maintenance of a homeostatic P . Our data thus show that collagen-binding β -integrins, integrin α β and ECM structure are potential targets for novel therapy aimed at modulating oedema formation and hypovolemic shock during anaphylaxis.
本研究的核心问题是什么?胶原结合β整合素在体内对真皮间质液压力(P)的细胞控制中发挥生理功能,从而参与血管外液体积的控制。在通过注射化合物48/80模拟的过敏反应期间,整合素αβ接管了这一生理功能。在此,我们探讨了整合素αβ是否能够替代胶原结合β整合素以维持长期的稳态P。主要发现及其重要性是什么?缺乏胶原结合整合素αβ的小鼠在间质生理学方面表现出复杂的真皮表型,这在P的控制中很明显。值得注意的是,在这些动物中,化合物48/80不会降低真皮P。我们目前的数据表明,整合素αβ可能是接管了胶原结合β整合素维持稳态P作用的候选者。更好地理解参与P控制的分子过程有助于建立控制过敏反应和感染性休克中水肿形成的新治疗方案。
积累的数据表明,体外重组胶原凝胶的细胞介导收缩可作为体内细胞介导的间质液压力(P)控制的模型。已经确定胶原结合β整合素在这两个过程中起核心作用。此外,在体外胶原结合β整合素受到干扰后,整合素αβ在介导收缩中取代了胶原结合β整合素的作用。整合素αβ对于因体内用化合物48/80(C48/80)使肥大细胞脱颗粒而降低的真皮P的正常化也很重要。在此,我们证明了整合素αβ在缺乏胶原结合整合素αβ(α11小鼠)的小鼠中维持长期稳态真皮P的作用。在循环停止后进行P的测量。此外,体外细胞介导的整合素αβ导向的胶原凝胶收缩取决于能否自由接触已知能结合几种细胞外基质(ECM)蛋白的胶原位点,这些蛋白形成αβ导向的细胞附着底物,如纤连蛋白和纤维蛋白。一种链球菌胶原结合蛋白CNE特异性结合并阻断胶原三螺旋上的这个位点。在此我们表明,虽然CNE干扰了C48/80后αβ导向的和血小板衍生生长因子BB诱导的真皮P正常化,但它不影响αβ依赖的稳态真皮P的维持。这些数据表明,在P的急性病理生理调节过程中需要对ECM结构进行动态修饰,但对于稳态P的长期维持则不需要。因此,我们的数据表明,胶原结合β整合素、整合素αβ和ECM结构是旨在调节过敏反应期间水肿形成和低血容量性休克的新疗法的潜在靶点。